Heat Biologics, Inc. Aktie News

500,000+ square foot facility  to support commercial-scale biomanufacturing

DURHAM, N.C., April 14, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system and novel biodefense assets, today announced it plans to host an investor and media livestream event on Tuesday, April 19, 2022 at 10:30 AM Eastern Time to discuss the latest ...

Burel to support anthrax and RapidVax™ biodefense initiatives as a platform for rapid response to known and unknown biological threats Burel to support anthrax and RapidVax™ biodefense initiatives as a platform for rapid response to known and unknown biological threats

Completed first phase of contract for $50 million; HHS options to procure up to $31 million of ANTHIM by the first half of 2023

Elusys' ANTHIM® is approved for the treatment of inhalation anthrax in the U.S., Canada, Europe and the United Kingdom Elusys' ANTHIM® is approved for the treatment of inhalation anthrax in the U.S., Canada, Europe and the United Kingdom

Designed for rapid “plug and play” programming and stockpiling against emerging infectious agents and viral mutations

DURHAM, N.C., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced the appointment of Paul Tebbey, Ph.D. as Senior Vice President of Product Development and Portfolio Strategy.

DURHAM, N.C., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Jeff Wolf, Chief Executive Officer of Heat Biologics, will be presenting at the Cantor Fitzgerald Global Healthcare Conference being held virtually between September 27-...